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Abstract: Galectin-1 (Gal-1) is known to regulate cell signaling within the immune system 
and may be a target for new anticancer immune therapy. In patients with chronic lymphocytic 
leukemia (CLL) and classical Hodgkin lymphoma (cHL), high levels of Gal-1 within the tumor 
microenvironment were associated with worse disease state or poor outcome. Gal-1 can be 
secreted from cells by an unknown mechanism, and levels in blood samples were associated 
with high tumor burden and worse disease state in cHL and CLL patients. However, serum levels 
of Gal-1 have never been investigated in patients with multiple myeloma (MM). We measured 
serum Gal-1 levels in samples from patients with treatment demanding MM at the time of 
diagnosis (n=102) and after treatment (n=24) and examined associations of serum Gal-1 with 
clinicopathological information obtained from patient medical records, as well as data on bone 
marrow angiogenesis and the macrophage activation biomarkers soluble CD163 (sCD163) 
and soluble mannose receptor. Serum Gal-1 levels were not elevated in patients with MM at 
diagnosis compared with healthy donors (median values 8.48 vs 11.93 ng/mL, P=0.05), which 
is in contrast to results in cHL and CLL. Furthermore, Gal-1 levels did not show association 
with bone marrow angiogenesis, clinicopathological parameters, overall survival, or response 
to treatment. There was a statically significant association between Gal-1 and sCD163 levels 
(R=0.24, P=0.02), but not with soluble mannose receptor (P=0.92). In conclusion, our results 
indicate that Gal-1 is not an important serum biomarker in MM, which is in contrast to data from 
patients with cHL and CLL. However, the association with sCD163 is in line with previous data 
showing that Gal-1 may be involved in alternative (M2-like) activation of macrophages.
Keywords: galectin-1, multiple myeloma, macrophage, soluble CD163, soluble mannose 
receptor, angiogenesis
Introduction
Galectins comprise a 15-member family of lectins (carbohydrate-binding proteins), of 
which some are widely distributed in various tissues and others are more confined.1,2 
Galectins exert diverse functions by binding to carbohydrate moieties on, for example, 
extracellular proteins, but they also function intracellularly where they are involved 
in cell signaling processes.1 Furthermore, galectins have been linked with the regu-
lation of hematopoiesis and modulation of the immune system in both acute and 
chronic inflammation.1,3
Galectin-1 (Gal-1) is involved in regulating homeostasis and differentiation of 
both T and B cells, can skew an immune reaction in a T
H
2-like (anti-inflammatory) 
direction, and may sway monocyte/macrophage polarization toward an alternatively 
activated (M2-like) phenotype.4,5 Importantly, studies have indicated that inhibition 
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of Gal-1 signaling may affect immune activation, and thus 
could be a strategy for new anticancer therapy.6,7
In a study on classical Hodgkin lymphoma (cHL) patients, 
Gal-1 was expressed by Hodgkin and Reed–Sternberg cells 
as well as macrophages and endothelial cells. Interestingly, 
high expression of Gal-1 within the tumor microenvironment 
was associated with poor survival.8
Gal-1 can be secreted from cells by an unknown 
mechanism1 and can be measured in blood samples.9,10 
In patients with chronic lymphocytic leukemia (CLL), both 
bone marrow and plasma levels of Gal-1 were increased in 
patients with progressive compared with stable disease, and 
CLL-supporting myeloid cells were found to be the major 
producers of Gal-1.11 In cHL patients, serum Gal-1 levels 
were increased compared with healthy controls and associ-
ated with clinical features of high tumor burden.9
Multiple myeloma (MM) is the second most common 
hematological malignancy, in which malignant plasma cells 
(PCs) proliferate within the bone marrow, leading to ane-
mia, bone destruction, and renal failure.12 The bone marrow 
microenvironment is known to be of major importance in 
the disease. Recently, macrophages have been reported as 
important supportive cells in MM, at least in part because 
of the promotion of MM cell growth and resistance to 
therapy,13 and infiltration by CD163+ macrophages in the 
bone marrow is associated with poor outcome in MM.14,15 
Within the few reports addressing the role of galectins in 
MM, one study indicated that Gal-1 increased prolifera-
tion and survival of CD45RAneg MM cells.16 A recent study 
reported increased Gal-1 mRNA expression in CD138+ bone 
marrow cells of MM patients, and that Gal-1 may be impor-
tant in MM-induced angiogenesis.17 Increased bone marrow 
angiogenesis is a characteristic feature of MM, where high 
level of angiogenesis is associated with poor outcome,18 and 
interestingly, Gal-1 may be involved in the regulation of 
angiogenesis in various human cancers.19
However, levels of serum Gal-1 have never been reported 
for patients with MM. Therefore, the aim of this study was 
to determine Gal-1 levels in patients with newly diagnosed 
MM and investigate associations with clinicopathological 
parameters, bone marrow angiogenesis, markers of mac-
rophage activation, and patient outcome.
Patients and methods
Patients
The cohort used in this study consists of 102 patients with 
newly diagnosed, treatment demanding MM, included at the 
Department of Hematology, Aarhus University Hospital, 
Aarhus, Denmark, from 1991 to 2004. With data from the 
same cohort of patients, we have previously published results 
on the macrophage-derived biomarkers soluble CD163 and 
soluble CD206/mannose receptor (sCD163 and sMR).20,21 
Basic characteristics of the included patients have been 
thoroughly described previously.20 Briefly, patients were 
treated with either conventional peroral chemotherapy 
(e.g., melphalan) and prednisolone (MP, 60%) or high-dose 
melphalan with autologous stem cells support (high dose 
therapy [HDT], 40%). We obtained a serum sample from the 
time of diagnosis and measured Gal-1 concentration. Of the 
included patients, 54% were male, median age at diagnosis 
was 60 years (range 39–84 years), and the heavy chain class 
subtypes were IgG: 58%, IgA: 25%, and light chain only: 
17%. Furthermore, for 24 patients, we were able to measure 
serum Gal-1 in a sample taken 3 months after HDT. Data 
from a previously published study in which we have mea-
sured serum Gal-1 in 30 healthy donors were included as a 
control group: 53% male, median age 53 years (range 45–66 
years).10 All samples were stored at −80°C.
Information about basic characteristics, pathology, and 
biochemistry results was obtained from patient medical 
records. Response to treatment was categorized as 1) complete 
response (CR) or 2) less than CR. CR was defined as negative 
serum and urine M-protein by electrophoresis and ,5% PCs 
in the bone marrow. Data on bone marrow angiogenesis, mea-
sured as CD34+ micro-vessel density (MVD), were obtained 
during a previous study and are described in detail in the 
study by Andersen et al.18 The study was approved by the 
central Denmark region committee on health research ethics 
(M-20100171). The requirement for study-specific informed 
consent was waived due to the retrospective nature of the 
study and the long follow-up time since inclusion.
Measurement of serum gal-1
Serum Gal-1 levels were measured using a time-resolved 
immunofluorometric assay as described previously.10 Micro-
titer wells were coated with capture antibody (AF1152, 
R&D Systems) at 2 µg/mL in phosphate-buffered saline 
(PBS)/pH 8 for 2 h. Plates were washed and blocked for 1 h 
(PBS, pH 7.4, 1% [v/v] Tween20). The wells were washed 
and standards or diluted serum (1:4) were added (dilution in 
assay buffer: PBS, pH 7.4, 25 µM ethylenediaminetetraacetic 
acid, 0.05% [v/v] human serum albumin, 1% [v/v] Tween20, 
0.9% [w/v] NaCl) and incubated for 2 h at room tempera-
ture. Following incubation with biotin-conjugated detection 
antibody (BAF1152, R&D Systems) at 0.1 µg/mL in assay 
buffer supplemented with europium-labeled streptavidin 
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(PerkinElmer) diluted 1:1,000, DELFIA enhancement solu-
tion (PerkinElmer) was added and plates were read in a time-
resolved fluorometer (Victor3, PerkinElmer). A standard 
curve of full-length recombinant Gal-1 (1152-GA, R&D 
Systems) at concentrations of 100–0.78 ng/mL was fitted 
using a 4-parameter nonlinear regression curve for each plate. 
All samples were run in duplicates, with mean %CV of 2.62 
in the included samples. Two samples were excluded from 
further analysis due to %CV.10%. Four donor samples 
were run in duplicate (CV,3.5%) on every plate, yielding 
a mean inter-plate CV of 15% (range 7%–21%). Previous 
measurements showed stability of Gal-1 over a year of 
repeated freeze/thaw cycles. Furthermore, when correlating 
the measured Gal-1 concentration with a storage time at 
−80°C, we found no indication of a time-dependent change in 
Gal-1 concentration (data not shown). In this study, three and 
five samples from patients and healthy donors, respectively, 
showed a concentration above the range of the standard curve 
(400 ng/mL). These samples were included in the statistical 
analyses with a concentration of 400 ng/mL.
statistical analyses
Statistical analyses were done using Stata version 11 for 
Mac (StataCorp LP, TX, USA). Figures were made using 
Prism 5 for Mac (GraphPad software Inc., CA, USA). 
Differences between groups were tested using paired or 
unpaired t-tests and one-way analysis of variance, when 
appropriate. Gaussian distribution of data was assessed by 
Q–Q plots before analysis, and non-normally distributed data 
were log-transformed before analysis. For investigation of 
linear associations between parameters, we used Pearson’s 
correlation analyses. Survival analyses were performed 
using Cox proportional hazards regression. All Gal-1 con-
centrations are reported as median values with interquartile 
range in parentheses. P-values of ,0.05 were considered 
statistically significant.
Results
serum gal-1 at the time of diagnosis 
and after hDT
Data on the measurements of Gal-1 concentrations in serum 
samples from 102 patients with newly diagnosed MM and 
30 healthy donors are shown in Figure 1. The Gal-1 levels 
displayed relatively large variation for both patients and con-
trols, with median values: MM, 8.48 ng/mL (5.75–14.78) and 
controls, 11.93 ng/mL (6.23–80.91), which was a borderline 
statistically significant difference (P=0.05). In Figure 2, Gal-1 
levels are shown in relation to international staging system 
stage,22 showing no clear association between Gal-1 levels 
and international staging system stage at the time of diagnosis 
(P=0.10). Using correlation analyses, we examined associa-
tions of Gal-1 with various clinicopathological parameters, but 
found no statistically significant associations: gender (P=0.82), 
age at diagnosis (P=0.18), creatinine (P=0.12), albumin 
(P=0.31), C-reactive protein (P=0.57), beta-2 microglobulin 
(P=0.93), and bone marrow PC infiltration (P=0.16).
In the 24 patients for whom we obtained serial samples, 
we found no statistically significant difference between Gal-1 
levels at diagnosis and 3 months after (Figure 1, P=0.13).
association of serum gal-1 levels 
to treatment response and outcome
For the 41 patients treated with HDT, we had access to data 
on the response to treatment. In these patients, there was no 
association with treatment response for either Gal-1 levels 
Figure 1 serum gal-1 in MM patients pre- and posttreatment.
Notes: serum gal-1 levels in healthy donors (n=30), patients with newly diagnosed 
MM (n=102), and for MM patients 3 months after hDT (n=24). Bars show median 
and interquartile range. *P=0.05.
Abbreviations: gal-1, galectin-1; hDT, high dose treatment; MM, multiple myeloma; 
NS, not significant.
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at diagnosis and at 3 months after HDT or for the change in 
Gal-1 during the course of treatment (all P.0.05).
To investigate whether serum Gal-1 was a prognostic 
marker in the cohort of patients with MM, we performed a 
Cox proportional hazards regression analyses with Gal-1 as 
a continuous variable, showing that Gal-1 was not a prog-
nostic factor, for patients treated neither with MP (n=61, 
hazard ratio [HR] =0.99, P=0.97) nor with HDT (n=41, 
HR =1.02, P=0.90).
gal-1 and bone marrow angiogenesis
Previously, we have shown that high levels of bone marrow 
angiogenesis are associated with poor outcome in MM.18 
In Figure 3, serum Gal-1 levels are plotted by angiogenesis 
level, using our previously published data on bone marrow 
angiogenesis measured as MVD (split on median). There was 
a trend toward slightly higher serum Gal-1 levels in patients 
with highest MVD, but the difference was not statistically 
significant (P=0.11).
In our previous study, serum levels of syndecan-1 asso-
ciated positively with bone marrow angiogenesis and with 
poor patient outcome.18 In this study, we also found a positive 
linear association of serum Gal-1 with syndecan-1 levels 
(Figure 4A, n=49, R=0.36, P=0.01).
gal-1 and markers of macrophage 
activation
Because Gal-1 may be produced by myeloid cells, as reported 
for patients with CLL,11 and may induce M2 polarization 
of macrophages, we examined possible associations with 
monocyte/macrophage-derived sCD163 and sMR. At the 
time of diagnosis, serum Gal-1 was positively associated with 
sCD163 (n=102, R=0.24, P=0.02 [Figure 4B]). However, 
there was no association of Gal-1 with sMR (n=102, P=0.92). 
At 3 months after HDT, there was a borderline significant 
association with both sCD163 (P=0.07) and sMR (P=0.05; 
data not shown).
Discussion
Recent years have seen a surge in the interest of galectin 
involvement in cancer pathophysiology,2 and blood levels 
of Gal-1 have been associated with more severe disease in 
hematological malignancies.9,11
However, serum levels of Gal-1 have not previously been 
reported in patients with MM. In a cohort of 102 patients 
with newly diagnosed, treatment demanding MM, we 
found no association between serum Gal-1 at diagnosis, 
tumor burden (bone marrow PC infiltration), or with overall 
patient survival. These findings indicate that Gal-1 is not an 
Figure 2 serum gal-1 in multiple myeloma patients according to iss stage.
Notes: serum gal-1 levels at time of diagnosis in patients with multiple myeloma, 
stratified by ISS stage. Bars show median and interquartile range.
Abbreviations: Gal-1, galectin-1; ISS, international staging system; NS, not significant.
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Figure 3 serum gal-1 and bone marrow angiogenesis.
Notes: Serum Gal-1 levels at time of diagnosis, stratified by bone marrow 
angiogenesis level measured as MVD, spilt on median MVD. Bars show median and 
interquartile range.
Abbreviations: Gal-1, galectin-1; MVD, micro-vessel density; NS, not significant.
6HU
XP
*DO
Q
JP
/
16








/RZHVW09' +LJKHVW09'
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
03
-M
ay
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1981
serum gal-1 in multiple myeloma
important serum biomarker in MM, in contrary to what has 
been shown for cHL and CLL.9,11 This is further supported 
by the finding that serum Gal-1 levels were not increased in 
MM patients compared with healthy controls, opposed to the 
results in cHL and CLL.
In a recent study, high expression of Gal-1 mRNA expres-
sion in purified CD138+ bone marrow cells correlated with 
worse outcome for MM patients.17 Gal-1 is expressed by 
endothelial cells and has been shown to be a proangiogenic 
growth factor,19 and in this study, there was a trend toward 
higher Gal-1 in patients with high MVD, but there was no sta-
tistically significant association between the two parameters. 
Storti et al reported high Gal-1 expression in hypoxic condi-
tions, and inhibition of Gal-1 in MM cells decreased expres-
sion of proangiogenic genes and reduced tumor burden and 
angiogenesis (MVD) in mouse models.17 Thus, this study 
indicates an important role for Gal-1 in CD138+ cells, but 
from our results, this may not be translated into measurable 
Gal-1 protein in serum. Hence, the limitation of this study is 
that we only had access to blood samples, and not samples 
of bone marrow. Therefore, future studies on Gal-1 in MM 
should include bone marrow samples for gene expression 
analysis, and, especially, protein level analyses on CD138+ 
cells may provide further insight into the role of Gal-1 in 
MM pathophysiology.
In CLL and cHL, Gal-1 is expressed by both malignant 
and tumor-supporting cells.8,11 Gal-1 may influence the 
activation state of macrophages inducing a less inflamma-
tory (M2-like) phenotype, which has been associated with 
poor outcome in several human cancers.23 In cHL, tissue 
expression of Gal-1 was correlated with CD163, which is 
a marker of M2-activated macrophages.8 In MM, higher 
infiltration of CD163-expressing macrophages is associ-
ated with shorter survival,14 and we have previously shown 
that sCD163 is associated with overall survival in MM.20 In 
this study, we found a positive association between the levels 
of serum Gal-1 and sCD163, which support the previous find-
ings indicating that Gal-1 may be associated with alternative 
macrophage activation.5
Thus, one explanation for the present results may be that 
the increased mRNA expression of Gal-1 in MM CD138+ 
bone marrow cells17 is not translated into increased protein 
levels, or that the increase is not reflected in the peripheral 
blood, resulting in serum levels not being significantly higher 
in patients with MM than in healthy controls. This should be 
investigated in future studies.
In conclusion, the serum levels of Gal-1 were not 
increased in patients with MM (compared with healthy 
donors) and did not show association with known prognostic 
factors or patient survival, which is in contrast to published 
data from patients with other hematological malignancies. 
However, serum Gal-1 levels were associated with monocyte/
macrophage-derived sCD163, supporting the involvement of 
Gal-1 in alternative (M2-like) activation of macrophages.
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